Abstract | OBJECTIVE: DESIGN: Multicentre, randomised, double-masked, vehicle-controlled, clinical trial. METHODS: A total of 183 patients were enrolled and randomised to either CsA 1% (group A), CsA 0.05% (group B) or vehicle only (group C). The main objective was to evaluate the efficacy of CsA aqueous solution in the reduction of signs and symptoms in patients with moderate to severe dry eye disease. RESULTS: An early (day 21) statistically significant improvement (p<0.05) was evident in four symptoms and three ocular signs in group A. An equivalent improvement in three symptoms and three ocular signs was demonstrated in group B. A significant improvement was identified in two symptoms and two ocular signs in group C. Comparing the three groups together, group A performed better in four symptoms than group B did with just one symptom. Group C did not show significant improvement. At day 42, group A showed improvement in four symptoms, while group B showed improvement in one symptom and one ocular sign. CONCLUSIONS:
|
Authors | Leopoldo Baiza-Durán, Javier Medrano-Palafox, Everardo Hernández-Quintela, Jaime Lozano-Alcazar, J Félix Alaníz-de la O |
Journal | The British journal of ophthalmology
(Br J Ophthalmol)
Vol. 94
Issue 10
Pg. 1312-5
(Oct 2010)
ISSN: 1468-2079 [Electronic] England |
PMID | 20679084
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Drug Carriers
- Ophthalmic Solutions
- Cyclosporine
|
Topics |
- Aged
- Cyclosporine
(administration & dosage, adverse effects)
- Drug Carriers
(administration & dosage)
- Dry Eye Syndromes
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Ophthalmic Solutions
(administration & dosage, adverse effects)
- Treatment Outcome
|